Soussi, T
Wiman, K G
Article History
Received: 5 February 2015
Revised: 31 March 2015
Accepted: 1 April 2015
First Online: 29 May 2015
Competing interests
: KGW is a co-founder, shareholder and board member of the company Aprea AB that develops p53-based cancer therapy, including APR-246. TS declares no conflict of interest.